ArticleAbdominal radiology (New York)2026
A multicenter study of automatic segmentation-based multimodal fusion integrating radiomics, deep learning, and clinical parameters for prostate cancer detection.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Apparent diffusion coefficient-based single-sequence radiomics integrated with clinical variables and Prostate Imaging Reporting and Data System for predicting clinically significant prostate cancer.Translational andrology and urology · 2026Article
- AI-assisted segmentation-based fusion model integrating deep learning, radiomics, and clinical parameters for identifying coronary heart disease risk in patients with MAFLD.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo develop and validate an interpretable machine learning model integrating radiomics, deep learning (DL), and clinical features based on automated MRI segmentation for detecting prostate cancer (PCa).
methodsThis retrospective multicenter study included 433 prostate patients. The internal cohort comprised 346 patients, who were randomly divided into a training set (n = 242) and an internal validation set (n = 104) at a 7:3 ratio. Automated prostate segmentation was performed on T2-weighted imaging and apparent diffusion coefficient maps using TotalSegmentator. Radiomics features were extracted and selected via mutual information, mRMR, LASSO, and Pearson correlation analysis. The DL labels were derived from a DenseNet-121 convolutional neural network. Using the eXtreme Gradient Boosting (XGBoost) algorithm, we constructed four types of prediction models: clinical models, radiomics models, DL models, and combined models integrating all three feature types (clinical, radiomics, and DL features). Model performance was evaluated using area under the curve (AUC) and related metrics. An external test set of 87 patients was used to validate the predictive performance of each model. Finally, SHapley Additive exPlanations (SHAP) were applied to enhance model interpretability and quantify the impact of individual features.
resultsThe combined model integrating radiomics, DL, and clinical features achieved the highest AUC of 0.902 (95% CI 0.841-0.962) in the external test set, outperforming individual models. SHAP analysis revealed prostate-specific antigen density and DL label as dominant predictors and provided transparent global and local interpretations of model decisions.
conclusionThe combined model integrating clinical, radiomics, and DL features based on automated MRI segmentation, achieved high accuracy and promising clinical utility in PCa detection.
Indexed as
Identifiers
42101624What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.